Last reviewed 2026-04-23 · How we verify

Cetuximab Induction

Cetuximab is a monoclonal antibody that targets and binds to the epidermal growth factor receptor (EGFR), preventing its activation and subsequent signaling.

Cetuximab is a monoclonal antibody that targets and binds to the epidermal growth factor receptor (EGFR), preventing its activation and subsequent signaling. Used for Colorectal cancer, Head and neck cancer.

At a glance

Mechanism of action

This mechanism of action is based on the role of EGFR in promoting cell proliferation and survival in various cancers. By blocking EGFR, cetuximab can inhibit tumor growth and induce apoptosis in cancer cells.

Approved indications

• Colorectal cancer
• Head and neck cancer

Common side effects

• Skin rash
• Fatigue
• Diarrhea
• Hypomagnesemia
• Hypokalemia

Key clinical trials

• A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) (PHASE1, PHASE2)
• A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer (PHASE2)
• A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer (PHASE2)
• CIML NK Cell in Head & Neck Cancer (PHASE1)
• Bioelectrical Impedance Analysis for Perioperative Fluid Evaluation in Colorectal Cancer Surgery (NA)
• Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. (PHASE2)
• Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status (PHASE4)
• Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.